Deldeprevir sodium  (Synonyms: ACH-2684 sodium; Neceprevir sodium)

Deldeprevir (ACH-2684; Neceprevir) sodium is a HCV NS3/4A protease inhibitor and resistance inhibitor. Deldeprevir sodium exhibits activity against wild-type genotype 1a and 1b HCV, including mutant strains resistant to other NS3 protease inhibitors. Deldeprevir sodium blocks the emergence of HCV mutant strains resistant to ACH-3422 in vitro, with enhanced efficacy when used in triple combination with ACH-3422 and ACH-3102 (HY-124182). Deldeprevir sodium shows additive antiviral potency when combined with ACH-3422, and exerts antiviral activity against HCV replicons carrying ACH-3102. Deldeprevir sodium is applicable to research related to hepatitis C^[1][2][3].

Deldeprevir sodium (3 days; antiviral combination study) exhibits higher in vitro potency against genotype-1a and 1b HCV replicons than BMS-032, and its combination with ACH-3102 reduces the emergence of resistance variants in these replicon cell lines^[1].
ACH-2684 (Deldeprevir sodium) (3 days) exhibits higher in vitro potency against genotype 1a and 1b HCV replicons than a reference NS3 protease inhibitor, and displays additive or synergistic antiviral efficacy when combined with a HCV NS5A inhibitor while reducing resistance variant emergence^[2].
Combining Deldeprevir sodium with the NS5B nucleotide inhibitor ACH-3422, or with ACH-3422 plus the NS5A inhibitor ACH-3102, enhances antiviral activity and blocks the emergence of ACH-3422-resistant HCV replicons in vitro^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

933.07

C₄₅H₅₅F₂N₆NaO₈S₂

1298053-61-8

O=C([C@]([C@]1([H])/C=C\CCCCC[C@@H]2CC(N3CC(F)(F)CCC3)=O)(C1)NC([C@@](C[C@@H](OC4=CC(C5=NC(C(C)C)=CS5)=NC6=C(C)C(OC)=CC=C46)C7)([H])N7C2=O)=O)N([Na])S(=O)(C8CC8)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zhao Y, et al. In VitroStudies Demonstrate a High Probability of Curing Genotype-1 Hepatitis C Patients with Combination of a Novel NS3 Protease Inhibitor ACH-2684 and a Novel NS5A Inhibitor ACH-3102: 1886[J]. Hepatology, 2012, 56: 1071A-1072A.

  [2]. Baglino S L, et al. Pegylated Interferons Lambda-1a and Alfa-2a Display Different Gene Induction and Cytokine Release Profiles in Both Human Hepatocytes and Peripheral Blood Mononuclear Cells: 1885[J]. Hepatology, 2012, 56: 1071A.

  [3]. Zhou X J, et al. Pharmacokinetics and Drug-Drug Interaction between Samatasvir, an NS5A Inhibitor, and Co-administered Simeprevir, an NS3/4A Protease Inhibitor, and Low Dose Ritonavir-Boosted TMC647055, a Non-Nucleoside NS5B Inhibitor, in Healthy Volunteers and HCV-Infected Subjects: 1987[J]. Hepatology, 2014, 60: 1167A-1168A.